Sources say GlaxoSmithKline (GSK) is poised to buy Human Genome Sciences (HGSI) for ~$2.8B, with...


Sources say GlaxoSmithKline (GSK) is poised to buy Human Genome Sciences (HGSI) for ~$2.8B, with an announcement likely during today's premarket session. The deal terms have reportedly been sweetened to $14/share from $13/share.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs